Adrenal Disorder Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

The adrenal glands are paired pyramid-shaped organs situated on top of each kidney, each composed of an outer cortex (producing glucocorticoids such as cortisol, mineralocorticoids such as aldosterone, and adrenal androgens) and an inner medulla (producing catecholamines — adrenaline and noradrenaline). Disorders of adrenal function are clinically significant because these hormones govern blood pressure, electrolyte balance, glucose metabolism, stress response, and immune function. Adrenal disorders are broadly divided into conditions of hormone excess (hypercortisolism in Cushing's syndrome, hyperaldosteronism in Conn's syndrome, catecholamine excess in phaeochromocytoma), hormone deficiency (adrenal insufficiency in Addison's disease or secondary hypoadrenalism), and adrenal tumours (adenomas, carcinomas, metastases).

The cornerstone of adrenal disorder evaluation is biochemical testing followed by anatomical imaging. For suspected cortisol excess, initial screening uses a 24-hour urinary free cortisol measurement, a late-night salivary cortisol level, or the overnight 1 mg dexamethasone suppression test (DST). Elevated cortisol that fails to suppress with dexamethasone confirms Cushing's syndrome; ACTH levels then distinguish ACTH-dependent causes (pituitary or ectopic) from ACTH-independent causes (adrenal). For adrenal insufficiency, the short Synacthen (cosyntropin) stimulation test — measuring cortisol response to synthetic ACTH — provides reliable diagnosis. CT or MRI of the adrenal glands and pituitary, combined with functional imaging such as MIBG scintigraphy (for phaeochromocytoma) or FDG-PET, guides treatment planning. Adrenal incidentalomas — adrenal masses discovered incidentally on imaging performed for other reasons — require biochemical evaluation for functional activity and radiological assessment for malignancy risk.

Treatment of adrenal disorders is highly condition-specific and requires specialist endocrinological input. Management ranges from lifelong hormone replacement for adrenal insufficiency, through pharmacological inhibition of steroid synthesis for Cushing's syndrome, to surgical adrenalectomy for functioning adrenal tumours, adrenocortical carcinoma, or large adrenal incidentalomas.

Primary adrenal insufficiency (Addison's disease) is caused by autoimmune destruction of the adrenal cortex (80% of cases in high-income countries), resulting in deficiency of cortisol and aldosterone. It presents insidiously with fatigue, weight loss, hyperpigmentation (from elevated ACTH driving melanocyte receptors), nausea, abdominal pain, postural hypotension, hyponatraemia, and hyperkalaemia. Adrenal crisis — acute life-threatening cortisol deficiency triggered by intercurrent illness or surgery in an undiagnosed or under-replaced patient — presents with severe hypotension, vomiting, and collapse, requiring immediate IV hydrocortisone.

Cushing's syndrome (chronic cortisol excess) causes truncal obesity, moon face, buffalo hump, purple striae, proximal muscle weakness, hypertension, osteoporosis, diabetes, and immunosuppression. The most common cause (Cushing's disease) is a pituitary ACTH-secreting adenoma. Primary hyperaldosteronism (Conn's syndrome) — the most common cause of secondary hypertension — is caused by an aldosterone-producing adrenal adenoma or bilateral adrenal hyperplasia, presenting with resistant hypertension and hypokalaemia. Phaeochromocytoma — a catecholamine-secreting tumour of the adrenal medulla — presents with episodic hypertension, headache, sweating, and palpitations; it is potentially lethal if undiagnosed and must be excluded before any adrenal surgery or adrenal biopsy. Adrenocortical carcinoma is a rare but aggressive malignancy requiring specialist oncological management.

All patients with confirmed adrenal insufficiency require lifelong glucocorticoid and mineralocorticoid replacement therapy — there is no alternative treatment. Patients with Cushing's syndrome caused by a pituitary adenoma are candidates for transsphenoidal pituitary surgery as the primary treatment; medical therapy with cortisol synthesis inhibitors (metyrapone, ketoconazole, cabergoline, or pasireotide) is used before surgery, when surgery fails, or when surgery is contraindicated. For primary hyperaldosteronism, adrenal vein sampling (AVS) — sampling blood from each adrenal vein to lateralise aldosterone excess to one side — is required before recommending unilateral adrenalectomy versus bilateral medical treatment with mineralocorticoid receptor antagonists (spironolactone, eplerenone).

Phaeochromocytoma requires pre-operative alpha-adrenergic blockade (phenoxybenzamine or doxazosin) for 10–14 days before adrenalectomy to prevent hypertensive crises during surgery. Surgery is the treatment of choice for phaeochromocytoma except in patients with multiple bilateral tumours (associated with hereditary syndromes including MEN2, VHL, and SDH mutations) or widespread metastatic disease. All patients with adrenal incidentalomas over 4 cm require consideration of surgery due to increased risk of adrenocortical carcinoma; incidentalomas under 4 cm with non-functioning biochemistry require annual surveillance imaging.

Adrenal insufficiency is treated with hydrocortisone (the synthetic equivalent of cortisol) twice or three times daily in doses that mimic the normal circadian cortisol pattern (higher morning dose, lower afternoon/evening dose). Fludrocortisone (a synthetic mineralocorticoid) is added for primary adrenal insufficiency (Addison's disease) to replace aldosterone. Patients must be educated about sick day rules — doubling or tripling their hydrocortisone dose during intercurrent illness, surgical procedures, or significant physiological stress — and must carry an emergency hydrocortisone injection kit for use if oral medication cannot be retained. Medical alert identification (bracelet or card) is essential.

For Cushing's syndrome from adrenal adenoma, laparoscopic adrenalectomy is curative in the majority of cases and is the preferred surgical approach. Laparoscopic retroperitoneal adrenalectomy (posterior retroperitoneoscopic adrenalectomy, PRA) is an increasingly used minimally invasive approach that avoids entering the peritoneal cavity, with advantages in operating time, blood loss, and recovery. Open adrenalectomy is reserved for large tumours (above 10 cm) or suspected malignancy. For bilateral adrenal hyperplasia causing Cushing's syndrome, bilateral laparoscopic adrenalectomy results in permanent adrenal insufficiency and lifelong replacement therapy. Mitotane — a cytotoxic drug specific to the adrenal cortex — is used as adjuvant therapy for adrenocortical carcinoma after surgical resection and as primary treatment for unresectable disease, though response rates are modest and toxicity significant.

With appropriate hormone replacement, patients with adrenal insufficiency can lead normal, active lives. Modern hydrocortisone replacement regimens, particularly modified-release formulations (Plenadren) designed to mimic the normal cortisol circadian rhythm more closely than conventional immediate-release tablets, improve quality of life and metabolic parameters compared to conventional thrice-daily dosing. However, most patients with Addison's disease report reduced quality of life, fatigue, and social functioning limitations compared to the general population despite optimal replacement, highlighting the limitations of current replacement strategies.

Surgical treatment of aldosterone-producing adrenal adenoma by laparoscopic adrenalectomy achieves long-term cure of hypertension in approximately 35–40% of patients and significantly improves blood pressure control in the remainder, often allowing reduction in antihypertensive medications. Post-operative outcomes from phaeochromocytoma surgery at specialist endocrine surgery centres are excellent — mortality is below 1% with appropriate pre-operative preparation. Surgical cure of Cushing's syndrome (through transsphenoidal surgery for pituitary Cushing's or adrenalectomy for adrenal Cushing's) reverses the metabolic complications — hypertension, diabetes, osteoporosis, and cardiovascular risk — over months to years after normalisation of cortisol, though full recovery may take 18–36 months.

Adrenal insufficiency carries life-threatening risk of adrenal crisis if steroid replacement is inadequate during physiological stress. An adrenal crisis is a medical emergency presenting with severe hypotension, vomiting, abdominal pain, altered consciousness, and profound hyponatraemia — it requires immediate IV hydrocortisone 100 mg bolus followed by infusion, IV fluid resuscitation, and hospitalisation. Education of patients, families, and healthcare providers about sick day rules and the mandatory use of emergency hydrocortisone is a critical component of management.

Adrenalectomy complications include haemorrhage (the adrenal glands have a rich arterial supply), damage to adjacent structures (spleen, kidney, liver, pancreas), pneumothorax, and deep vein thrombosis. Conversion from laparoscopic to open surgery occurs in 2–5% of cases. Patients who have had unilateral adrenalectomy for cortisol-producing tumours (adrenal Cushing's) develop transient contralateral adrenal insufficiency from chronic suppression of the HPA axis, requiring prolonged post-operative glucocorticoid replacement (typically 6–24 months) until recovery. Patients with phaeochromocytoma who undergo inadequate pre-operative alpha-blockade may experience potentially fatal hypertensive crises or cardiovascular instability during surgical handling of the tumour.

Patients with adrenal insufficiency require lifelong endocrinology follow-up with periodic review of replacement dose adequacy, assessment for complications of both under-replacement (fatigue, hyperpigmentation in Addison's, weight loss) and over-replacement (weight gain, osteoporosis, hypertension, diabetes). Annual measurements of bone density and metabolic parameters are recommended. Education and re-education about sick day rules and emergency glucocorticoid management should be reinforced at every clinic visit.

After adrenalectomy for adrenal adenoma, patients undergo biochemical assessment at 6–12 weeks to confirm resolution of excess hormone secretion. For aldosteronoma, blood pressure response and potassium levels are monitored; ongoing antihypertensive medications are gradually reduced and discontinued where possible. Post-operative cortisol recovery after adrenal Cushing's requires regular cortisol measurement (morning fasting cortisol, short Synacthen test) to guide weaning of replacement hydrocortisone, which may take 1–3 years for full adrenal axis recovery. Adrenocortical carcinoma requires intensive oncological follow-up with CT surveillance every 3 months in the first 2 years.

Lifelong hydrocortisone and fludrocortisone replacement for adrenal insufficiency costs under $50 per month in most countries and is generally covered by prescription benefit schemes. Emergency hydrocortisone injection kits are available on prescription in most countries. Adrenal disorder investigation — including dynamic endocrine testing (Synacthen tests, dexamethasone suppression tests, CRH stimulation), adrenal vein sampling, and cross-sectional and functional imaging — carries significant upfront diagnostic costs of $1,500–5,000 depending on the tests required.

Laparoscopic adrenalectomy at a specialist endocrine surgery centre in the United States costs $15,000–30,000 including anaesthesia and hospitalisation. In India, laparoscopic adrenalectomy at a JCI-accredited hospital costs $3,000–6,000, representing savings of 70–80% compared to US pricing. Thailand, Turkey, and Malaysia offer similar procedures at comparable or slightly higher costs, with internationally trained endocrine surgeons and modern facilities. Specialist endocrinology consultations for complex adrenal disorders are available in India, Singapore, and Thailand at costs of $50–150 per consultation compared to $300–600 in the US.

For adrenal insufficiency, there are no alternatives to glucocorticoid and mineralocorticoid replacement — these hormones are physiologically essential for life and cannot be replicated by any non-pharmacological approach. For non-functioning adrenal adenomas under 4 cm without evidence of hormonal activity, surveillance with repeat imaging and biochemical testing every 12 months is an alternative to surgery, particularly in patients with significant surgical risk.

For primary hyperaldosteronism due to bilateral adrenal hyperplasia (not lateralisable on adrenal vein sampling), mineralocorticoid receptor antagonist therapy (spironolactone or eplerenone) is the alternative to surgery, providing effective blood pressure and potassium normalisation without the risks and recovery of adrenalectomy. Spironolactone is highly effective but causes anti-androgenic side effects (gynaecomastia, erectile dysfunction in men, menstrual irregularities) at the doses often required for blood pressure control; eplerenone is more selective with fewer hormonal side effects at higher cost. For Cushing's syndrome awaiting pituitary surgery or as a bridge to adrenalectomy, cortisol synthesis inhibitors (metyrapone, osilodrostat, ketoconazole) provide effective medical control.